Ansell Stock Earnings Reports

Ansell reported a strong FY25 with adjusted EPS of $1.26 (upper end of guidance), ~8% organic sales growth, 10% organic EBIT growth and a 30% dividend increase. Industrial delivered record sales and EBIT margin (mechanical and chemical performing well); Healthcare recovered with ~10% organic growth, driven by Exam, Surgical and Cleanroom (KBU drove double‑digit cleanroom growth). The Kimberly‑Clark PPE (KBU) acquisition integrated ahead of plan, delivering earlier‑than‑expected synergies and prompting an increase in the synergy target from $10m to $15m (with $5m realized in FY25). APIP (productivity program) largely complete on organization and manufacturing streams; IT/ERP rollouts are next (multi‑year, starting with North America) and expected to unlock further efficiencies. Management expects to fully offset new U.S. tariffs via pricing, sourcing flexibility and productivity; FY26 adjusted EPS guidance is $1.33–$1.45. Balance sheet remains healthy despite acquisition funding; net debt/EBITDA ~1.6x and management will resume an on‑market buyback program of up to $200m in FY26. Capital allocation priorities are internal growth and productivity (automation), targeted M&A that fits strategic lens, and returning excess capital to shareholders. Sustainability: net‑zero target extended to include Scope 3 (FY45) and SBTi validated.